NovelMatrix / Cell Culture Substrate
An animal-free recombinant coating that keeps suspension cells attached while they proliferate — with built-in EGF activity and gentle, enzyme-free release.
Cells that are natively suspension — CHO, Jurkat, hybridoma, primary immune cells, iPS-derived spheroids — can be held in an adherent state while proliferating. Live imaging, single-cell analytics and high-density culture, traditionally limited to adherent lines, become accessible to suspension systems.
An EGF-like domain fused into the FP2 region is designed to activate EGFR → PI3K/Akt, MEK/ERK signaling (EGF-dependence of intestinal organoids was established by Fujii et al. 2018 and later work). Media no longer require exogenous EGF, reducing cost and lot-to-lot variability. Novelglue-specific adhesion / proliferation data are reported in Kawakami et al. 2025.
Under defined conditions cells can be detached mechanically without trypsinization, preserving surface antigens and receptors that are typically damaged by enzymatic digestion. Suited for stem cell passaging and cell therapy harvest (consistent with the surface-marker preservation requirements discussed in Ayuso-Sacido et al. 2010).
Fully recombinant production avoids the lot-to-lot variation of Matrigel™ (Hughes et al. 2010) and the individual-animal / pathogen risks of natural mussel extracts like CellTak™. Aligned with FDA Modernization Act 2.0 and PMDA animal-free guidance.
Benchmark against representative commercial substrates, covering both research-use and GMP-grade scenarios.
| Item | NovelMatrix | Matrigel™ | iMatrix-511 | CellTak™ | Synthemax II |
|---|---|---|---|---|---|
| Origin | Recombinant MFP | Mouse sarcoma | Recombinant laminin E8 | Natural mussel | Synthetic peptide |
| Animal-free | Yes | No | Partial (CHO) | No | Yes |
| Suspension → adherent | Yes | Partial | Partial | Partial | No |
| Functional-domain cassette | Yes | No | No | No | No |
| Non-enzymatic release | Yes | No | No | Partial | Yes |
| Lot reproducibility | Very high | Low | High | Medium | Very high |
| GMP-ready | Yes | Difficult | Yes | Difficult | Yes |
References: Matrigel lot variation (Hughes 2010, Proteomics), EGF-dependent intestinal organoid maintenance (Fujii 2018, Cell Stem Cell), synthetic alternatives review (Aisenbrey & Murphy 2020, Nat Rev Mater), FP121 primary data (Kawakami 2025, Materials & Design).
Kawakami, Y. et al. (2025) Development of the FP121 series: Hybrid proteins mimicking marine adhesive proteins with cell adhesion and proliferation activity , Materials & Design .
View on ScienceDirect →Novelglue (FP121 シリーズ) の基盤論文。細胞接着・増殖活性・スクラッチアッセイ等の一次データを含む。
Fujii, M. et al. (2018) Human intestinal organoids maintain self-renewal capacity and cellular diversity in niche-inspired culture condition , Cell Stem Cell , 23 , pp. 787-793.e6 .
DOI: 10.1016/j.stem.2018.11.016EGF を含むニッチ因子に依存したヒト腸オルガノイド維持条件を示した代表論文。
Hughes, C. S., Postovit, L. M., Lajoie, G. A. (2010) Matrigel: A complex protein mixture required for optimal growth of cell culture , Proteomics , 10 , pp. 1886-1890 .
DOI: 10.1002/pmic.200900758Matrigel の組成の不均一性とロット間変動を定量的に評価。
Aisenbrey, E. A., Murphy, W. L. (2020) Synthetic alternatives to Matrigel , Nature Reviews Materials , 5 , pp. 539-551 .
DOI: 10.1038/s41578-020-0199-8Matrigel 代替としての合成・組換え基材の比較レビュー。
